Therapeutic efficacy and safety of one-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population

Dermatology. 1999;199(1):47-9. doi: 10.1159/000018177.

Abstract

Objective: To evaluate the efficacy and safety of a 1-week intermittent itraconazole dosing schedule for onychomycosis.

Methods: In this multicenter, open-label study, 646 patients received itraconazole 200 mg twice daily for 1 week/month, followed by 3 weeks without therapy. Patients with fingernail infections received 2 treatment cycles, patients with toenail or combined toenail and fingernail infections received 3 cycles. Efficacy was evaluated at week 9 (2-month regimen), week 13 (3-month regimen) and 3, 6 or 9 (toenails only) months after completion of therapy.

Results: Clinical and mycologic cure rates for fingernails were greater than 90% 6 months after completion of 2 treatment cycles. Clinical and mycologic cure rates for toenails were 84 and 98%, respectively, 9 months after completion of 3 cycles. Treatment was well tolerated; adverse events (mostly mild) occurred in 4.6% of patients.

Conclusion: A 1-week intermittent itraconazole dosing regimen is a safe and effective treatment for onychomycosis.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anorexia / chemically induced
  • Antifungal Agents / adverse effects
  • Antifungal Agents / therapeutic use*
  • Candida / drug effects
  • Candida / isolation & purification
  • China
  • Drug Administration Schedule
  • Female
  • Gastrointestinal Diseases / chemically induced
  • Humans
  • Itraconazole / adverse effects
  • Itraconazole / therapeutic use*
  • Male
  • Middle Aged
  • Nausea / chemically induced
  • Onychomycosis / drug therapy*
  • Onychomycosis / microbiology
  • Time Factors
  • Treatment Outcome
  • Trichophyton / drug effects
  • Trichophyton / isolation & purification
  • Xerostomia / chemically induced

Substances

  • Antifungal Agents
  • Itraconazole